FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198367048> ?p ?o ?g. }

• W3198367048 endingPage "S421" @default.
• W3198367048 startingPage "S421" @default.
• W3198367048 abstract "Context Belamaf is a B-cell maturation antigen-targeting antibody-drug conjugate approved in the US and EU for the treatment of RRMM. Ocular events (OEs) during the DREAMM-2 trial (NCT03525678) included corneal exam findings (punctate keratopathy and microcyst-like epithelial changes), BCVA changes, and ocular symptoms. Dose reductions or delays based on corneal exam findings and BCVA were used to manage OEs. Objective To study relationships between exam findings, BCVA changes, and patient-reported ocular symptoms in a post hoc analysis to explore if BCVA changes and symptoms alone could guide dosing. Methods Patients receiving single-agent belamaf (2.5 mg/kg) had eye evaluations (including a corneal exam and BCVA assessment of Snellen visual acuity) performed by ophthalmologists at baseline and prior to each dose. Changes in the corneal epithelium (Ker) and BCVA were assessed per protocol-defined criteria and assessment of grade was based on the worse eye. BCVA grading was relative to baseline. Patient-reported ocular symptoms were reported per the Common Terminology Criteria for Adverse Events. Results In 12.5% of eye evaluations Grade 3–4 Ker was associated with minimal or no (Grade ≤1) BCVA changes. When patient-reported ocular symptoms were also considered, only 7.5% of evaluations found Grade 3–4 Ker with Grade ≤1 BCVA changes or ocular symptoms. Mild or no (Grade ≤2) Ker was associated with Grade ≤1 BCVA changes in 59.5% of evaluations, or in 38.8% of evaluations with no ocular symptoms reported. Overall, Grade 3–4 Ker were found in 24.9% of evaluations; by contrast, patients had Grade 2–4 BCVA changes or ocular symptoms in 53.7% of evaluations. Conclusions BCVA changes and ocular symptoms should be further investigated to determine if they can be used as alternatives (e.g., frequency of eye examinations based on symptoms) for the management of belamaf dosing to potentially reduce the burden on patients and healthcare professionals. Funding GlaxoSmithKline (205678; NCT03525678). Drug linker technology licensed from Seagen Inc.; mAb produced using POTELLIGENT Technology licensed from BioWa. © 2021 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2021 ASCO Annual Meeting. All rights reserved. Belamaf is a B-cell maturation antigen-targeting antibody-drug conjugate approved in the US and EU for the treatment of RRMM. Ocular events (OEs) during the DREAMM-2 trial (NCT03525678) included corneal exam findings (punctate keratopathy and microcyst-like epithelial changes), BCVA changes, and ocular symptoms. Dose reductions or delays based on corneal exam findings and BCVA were used to manage OEs. To study relationships between exam findings, BCVA changes, and patient-reported ocular symptoms in a post hoc analysis to explore if BCVA changes and symptoms alone could guide dosing. Patients receiving single-agent belamaf (2.5 mg/kg) had eye evaluations (including a corneal exam and BCVA assessment of Snellen visual acuity) performed by ophthalmologists at baseline and prior to each dose. Changes in the corneal epithelium (Ker) and BCVA were assessed per protocol-defined criteria and assessment of grade was based on the worse eye. BCVA grading was relative to baseline. Patient-reported ocular symptoms were reported per the Common Terminology Criteria for Adverse Events. In 12.5% of eye evaluations Grade 3–4 Ker was associated with minimal or no (Grade ≤1) BCVA changes. When patient-reported ocular symptoms were also considered, only 7.5% of evaluations found Grade 3–4 Ker with Grade ≤1 BCVA changes or ocular symptoms. Mild or no (Grade ≤2) Ker was associated with Grade ≤1 BCVA changes in 59.5% of evaluations, or in 38.8% of evaluations with no ocular symptoms reported. Overall, Grade 3–4 Ker were found in 24.9% of evaluations; by contrast, patients had Grade 2–4 BCVA changes or ocular symptoms in 53.7% of evaluations. BCVA changes and ocular symptoms should be further investigated to determine if they can be used as alternatives (e.g., frequency of eye examinations based on symptoms) for the management of belamaf dosing to potentially reduce the burden on patients and healthcare professionals." @default.
• W3198367048 created "2021-09-13" @default.
• W3198367048 creator A5018048721 @default.
• W3198367048 creator A5041407463 @default.
• W3198367048 creator A5046804125 @default.
• W3198367048 creator A5048976307 @default.
• W3198367048 creator A5059967673 @default.
• W3198367048 creator A5064710410 @default.
• W3198367048 creator A5072021995 @default.
• W3198367048 creator A5080959881 @default.
• W3198367048 creator A5082564837 @default.
• W3198367048 creator A5082712392 @default.
• W3198367048 creator A5085703282 @default.
• W3198367048 creator A5091215609 @default.
• W3198367048 date "2021-09-01" @default.
• W3198367048 modified "2023-10-16" @default.
• W3198367048 title "MM-103: Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf)" @default.
• W3198367048 doi "https://doi.org/10.1016/s2152-2650(21)01944-3" @default.
• W3198367048 hasPublicationYear "2021" @default.
• W3198367048 type Work @default.
• W3198367048 sameAs 3198367048 @default.
• W3198367048 citedByCount "0" @default.
• W3198367048 crossrefType "journal-article" @default.
• W3198367048 hasAuthorship W3198367048A5018048721 @default.
• W3198367048 hasAuthorship W3198367048A5041407463 @default.
• W3198367048 hasAuthorship W3198367048A5046804125 @default.
• W3198367048 hasAuthorship W3198367048A5048976307 @default.
• W3198367048 hasAuthorship W3198367048A5059967673 @default.
• W3198367048 hasAuthorship W3198367048A5064710410 @default.
• W3198367048 hasAuthorship W3198367048A5072021995 @default.
• W3198367048 hasAuthorship W3198367048A5080959881 @default.
• W3198367048 hasAuthorship W3198367048A5082564837 @default.
• W3198367048 hasAuthorship W3198367048A5082712392 @default.
• W3198367048 hasAuthorship W3198367048A5085703282 @default.
• W3198367048 hasAuthorship W3198367048A5091215609 @default.
• W3198367048 hasConcept C118487528 @default.
• W3198367048 hasConcept C126322002 @default.
• W3198367048 hasConcept C151730666 @default.
• W3198367048 hasConcept C16005928 @default.
• W3198367048 hasConcept C197934379 @default.
• W3198367048 hasConcept C2777793932 @default.
• W3198367048 hasConcept C2778257484 @default.
• W3198367048 hasConcept C2779343474 @default.
• W3198367048 hasConcept C67761136 @default.
• W3198367048 hasConcept C71924100 @default.
• W3198367048 hasConcept C86803240 @default.
• W3198367048 hasConceptScore W3198367048C118487528 @default.
• W3198367048 hasConceptScore W3198367048C126322002 @default.
• W3198367048 hasConceptScore W3198367048C151730666 @default.
• W3198367048 hasConceptScore W3198367048C16005928 @default.
• W3198367048 hasConceptScore W3198367048C197934379 @default.
• W3198367048 hasConceptScore W3198367048C2777793932 @default.
• W3198367048 hasConceptScore W3198367048C2778257484 @default.
• W3198367048 hasConceptScore W3198367048C2779343474 @default.
• W3198367048 hasConceptScore W3198367048C67761136 @default.
• W3198367048 hasConceptScore W3198367048C71924100 @default.
• W3198367048 hasConceptScore W3198367048C86803240 @default.
• W3198367048 hasLocation W31983670481 @default.
• W3198367048 hasOpenAccess W3198367048 @default.
• W3198367048 hasPrimaryLocation W31983670481 @default.
• W3198367048 hasRelatedWork W2162581351 @default.
• W3198367048 hasRelatedWork W2216501909 @default.
• W3198367048 hasRelatedWork W2469262027 @default.
• W3198367048 hasRelatedWork W2569155901 @default.
• W3198367048 hasRelatedWork W2778957091 @default.
• W3198367048 hasRelatedWork W2801065673 @default.
• W3198367048 hasRelatedWork W3185164001 @default.
• W3198367048 hasRelatedWork W4281716650 @default.
• W3198367048 hasRelatedWork W4283455950 @default.
• W3198367048 hasRelatedWork W4288448365 @default.
• W3198367048 hasVolume "21" @default.
• W3198367048 isParatext "false" @default.
• W3198367048 isRetracted "false" @default.
• W3198367048 magId "3198367048" @default.
• W3198367048 workType "article" @default.